Search
ivonescimab
Indications:
- intestigational treatment of advanced PD-L1-positive advanced NSCLC
* improvement in progression-free survival vs pembrolizumab (median of 11.1 vs 5.8 months) in phase-3 trial [1]
Dosage:
- 20 mg/kg every 3 weeks
Adverse effects:
- proteinuria, hypertension, lab abnormalities.
Mechanism of action:
- bispecific antibody that targets PD-1 & VEGF
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Brooks M
Ivonescimab: Possible New First-Line Standard in PD-L1-Positive Advanced NSCLC.
Medscape. Sept 12, 2024
https://www.medscape.com/viewarticle/ivonescimab-possible-new-first-line-standard-pd-l1-positive-2024a1000g7m